Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SKW-2C
- Development stage
- Preclinical
- Lead developer
- Skye Biologics
- Administration
- Intradiscal, Local Injection
01
Overview
SKW-2C is a second-generation biological therapeutic developed by Skye Biologics for the treatment of degenerative conditions and diseases of the spine. Part of the company's '2nd Generation: Skye Biological Therapeutics' pipeline, it is a regenerative medicine product that utilizes naturally advanced human biological materials. The therapy is designed to promote tissue repair and healing in spinal tissues, likely leveraging bioactive components such as growth factors, cytokines, and extracellular matrix proteins derived from human placental or birth tissues to modulate inflammation and support structural regeneration.
Beyond the preview
Go deeper on SKW-2C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SKW-2C.